Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)

Ankit Kansagra, Noelle V. Frey, Merav Bar, Theodore W Laetsch, Paul A. Carpenter, Bipin N. Savani, Helen E. Heslop, Catherine M. Bollard, Krishna V. Komanduri, Dennis A. Gastineau, Christian Chabannon, Miguel A. Perales, Michael Hudecek, Mahmoud Aljurf, Leslie Andritsos, John A. Barrett, Veronika Bachanova, Chiara Bonini, Armin Ghobadi, Saar I. GillJoshua A. Hill, Saad Kenderian, Partow Kebriaei, Arnon Nagler, David Maloney, Hien D. Liu, Nirali N. Shah, Mohamed A. Kharfan-Dabaja, Elizabeth J. Shpall, Ghulam J. Mufti, Laura Johnston, Elad Jacoby, Ali Bazarbachi, John F. DiPersio, Steven Z. Pavletic, David L. Porter, Stephan A. Grupp, Michel Sadelain, Mark R. Litzow, Mohamad Mohty, Shahrukh K. Hashmi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

On August 30, 2017, the U.S. Food and Drug Administration (US-FDA) approved tisagenlecleucel (KYMRIAH, Novartis, Basel, Switzerland), a synthetic bioimmune product of anti-CD19 chimeric antigen receptor-T cells (CAR-T), for the treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). With this new era of personalized cancer immunotherapy, multiple challenges are present ranging from implementation of a CAR-T program to safe delivery of the drug, long-term toxicity monitoring and disease assessments. To address these issues, experts representing the American Society for Blood and Marrow Transplant (ASBMT), the European Group for Blood and Marrow Transplantation (EBMT), the International Society of Cell and Gene Therapy (ISCT), and the Foundation for the Accreditation of Cellular Therapy (FACT), formed a global CAR-T task force to identify and address key questions pertinent for hematologists and transplant physicians regarding the clinical use of anti CD19 CAR-T therapy in patients with B-ALL. This article presents an initial roadmap for navigating common clinical practice scenarios that will become more prevalent now that the first commercially available CAR-T product for B-ALL has been approved.

Original languageEnglish (US)
JournalBone Marrow Transplantation
DOIs
StatePublished - Jan 1 2019

Fingerprint

Expert Testimony
CD19 Antigens
T-Cell Antigen Receptor
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Antigen Receptors
B-Lymphocytes
Transplantation
Bone Marrow
Cell- and Tissue-Based Therapy
T-Lymphocytes
Transplants
Accreditation
Advisory Committees
United States Food and Drug Administration
Switzerland
Genetic Therapy
Immunotherapy
Young Adult
Physicians
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). / Kansagra, Ankit; Frey, Noelle V.; Bar, Merav; Laetsch, Theodore W; Carpenter, Paul A.; Savani, Bipin N.; Heslop, Helen E.; Bollard, Catherine M.; Komanduri, Krishna V.; Gastineau, Dennis A.; Chabannon, Christian; Perales, Miguel A.; Hudecek, Michael; Aljurf, Mahmoud; Andritsos, Leslie; Barrett, John A.; Bachanova, Veronika; Bonini, Chiara; Ghobadi, Armin; Gill, Saar I.; Hill, Joshua A.; Kenderian, Saad; Kebriaei, Partow; Nagler, Arnon; Maloney, David; Liu, Hien D.; Shah, Nirali N.; Kharfan-Dabaja, Mohamed A.; Shpall, Elizabeth J.; Mufti, Ghulam J.; Johnston, Laura; Jacoby, Elad; Bazarbachi, Ali; DiPersio, John F.; Pavletic, Steven Z.; Porter, David L.; Grupp, Stephan A.; Sadelain, Michel; Litzow, Mark R.; Mohty, Mohamad; Hashmi, Shahrukh K.

In: Bone Marrow Transplantation, 01.01.2019.

Research output: Contribution to journalArticle

Kansagra, A, Frey, NV, Bar, M, Laetsch, TW, Carpenter, PA, Savani, BN, Heslop, HE, Bollard, CM, Komanduri, KV, Gastineau, DA, Chabannon, C, Perales, MA, Hudecek, M, Aljurf, M, Andritsos, L, Barrett, JA, Bachanova, V, Bonini, C, Ghobadi, A, Gill, SI, Hill, JA, Kenderian, S, Kebriaei, P, Nagler, A, Maloney, D, Liu, HD, Shah, NN, Kharfan-Dabaja, MA, Shpall, EJ, Mufti, GJ, Johnston, L, Jacoby, E, Bazarbachi, A, DiPersio, JF, Pavletic, SZ, Porter, DL, Grupp, SA, Sadelain, M, Litzow, MR, Mohty, M & Hashmi, SK 2019, 'Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)', Bone Marrow Transplantation. https://doi.org/10.1038/s41409-019-0451-2
Kansagra, Ankit ; Frey, Noelle V. ; Bar, Merav ; Laetsch, Theodore W ; Carpenter, Paul A. ; Savani, Bipin N. ; Heslop, Helen E. ; Bollard, Catherine M. ; Komanduri, Krishna V. ; Gastineau, Dennis A. ; Chabannon, Christian ; Perales, Miguel A. ; Hudecek, Michael ; Aljurf, Mahmoud ; Andritsos, Leslie ; Barrett, John A. ; Bachanova, Veronika ; Bonini, Chiara ; Ghobadi, Armin ; Gill, Saar I. ; Hill, Joshua A. ; Kenderian, Saad ; Kebriaei, Partow ; Nagler, Arnon ; Maloney, David ; Liu, Hien D. ; Shah, Nirali N. ; Kharfan-Dabaja, Mohamed A. ; Shpall, Elizabeth J. ; Mufti, Ghulam J. ; Johnston, Laura ; Jacoby, Elad ; Bazarbachi, Ali ; DiPersio, John F. ; Pavletic, Steven Z. ; Porter, David L. ; Grupp, Stephan A. ; Sadelain, Michel ; Litzow, Mark R. ; Mohty, Mohamad ; Hashmi, Shahrukh K. / Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). In: Bone Marrow Transplantation. 2019.
@article{e623fa04d0da424ea102d3b63a9a901c,
title = "Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)",
abstract = "On August 30, 2017, the U.S. Food and Drug Administration (US-FDA) approved tisagenlecleucel (KYMRIAH, Novartis, Basel, Switzerland), a synthetic bioimmune product of anti-CD19 chimeric antigen receptor-T cells (CAR-T), for the treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). With this new era of personalized cancer immunotherapy, multiple challenges are present ranging from implementation of a CAR-T program to safe delivery of the drug, long-term toxicity monitoring and disease assessments. To address these issues, experts representing the American Society for Blood and Marrow Transplant (ASBMT), the European Group for Blood and Marrow Transplantation (EBMT), the International Society of Cell and Gene Therapy (ISCT), and the Foundation for the Accreditation of Cellular Therapy (FACT), formed a global CAR-T task force to identify and address key questions pertinent for hematologists and transplant physicians regarding the clinical use of anti CD19 CAR-T therapy in patients with B-ALL. This article presents an initial roadmap for navigating common clinical practice scenarios that will become more prevalent now that the first commercially available CAR-T product for B-ALL has been approved.",
author = "Ankit Kansagra and Frey, {Noelle V.} and Merav Bar and Laetsch, {Theodore W} and Carpenter, {Paul A.} and Savani, {Bipin N.} and Heslop, {Helen E.} and Bollard, {Catherine M.} and Komanduri, {Krishna V.} and Gastineau, {Dennis A.} and Christian Chabannon and Perales, {Miguel A.} and Michael Hudecek and Mahmoud Aljurf and Leslie Andritsos and Barrett, {John A.} and Veronika Bachanova and Chiara Bonini and Armin Ghobadi and Gill, {Saar I.} and Hill, {Joshua A.} and Saad Kenderian and Partow Kebriaei and Arnon Nagler and David Maloney and Liu, {Hien D.} and Shah, {Nirali N.} and Kharfan-Dabaja, {Mohamed A.} and Shpall, {Elizabeth J.} and Mufti, {Ghulam J.} and Laura Johnston and Elad Jacoby and Ali Bazarbachi and DiPersio, {John F.} and Pavletic, {Steven Z.} and Porter, {David L.} and Grupp, {Stephan A.} and Michel Sadelain and Litzow, {Mark R.} and Mohamad Mohty and Hashmi, {Shahrukh K.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41409-019-0451-2",
language = "English (US)",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)

AU - Kansagra, Ankit

AU - Frey, Noelle V.

AU - Bar, Merav

AU - Laetsch, Theodore W

AU - Carpenter, Paul A.

AU - Savani, Bipin N.

AU - Heslop, Helen E.

AU - Bollard, Catherine M.

AU - Komanduri, Krishna V.

AU - Gastineau, Dennis A.

AU - Chabannon, Christian

AU - Perales, Miguel A.

AU - Hudecek, Michael

AU - Aljurf, Mahmoud

AU - Andritsos, Leslie

AU - Barrett, John A.

AU - Bachanova, Veronika

AU - Bonini, Chiara

AU - Ghobadi, Armin

AU - Gill, Saar I.

AU - Hill, Joshua A.

AU - Kenderian, Saad

AU - Kebriaei, Partow

AU - Nagler, Arnon

AU - Maloney, David

AU - Liu, Hien D.

AU - Shah, Nirali N.

AU - Kharfan-Dabaja, Mohamed A.

AU - Shpall, Elizabeth J.

AU - Mufti, Ghulam J.

AU - Johnston, Laura

AU - Jacoby, Elad

AU - Bazarbachi, Ali

AU - DiPersio, John F.

AU - Pavletic, Steven Z.

AU - Porter, David L.

AU - Grupp, Stephan A.

AU - Sadelain, Michel

AU - Litzow, Mark R.

AU - Mohty, Mohamad

AU - Hashmi, Shahrukh K.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - On August 30, 2017, the U.S. Food and Drug Administration (US-FDA) approved tisagenlecleucel (KYMRIAH, Novartis, Basel, Switzerland), a synthetic bioimmune product of anti-CD19 chimeric antigen receptor-T cells (CAR-T), for the treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). With this new era of personalized cancer immunotherapy, multiple challenges are present ranging from implementation of a CAR-T program to safe delivery of the drug, long-term toxicity monitoring and disease assessments. To address these issues, experts representing the American Society for Blood and Marrow Transplant (ASBMT), the European Group for Blood and Marrow Transplantation (EBMT), the International Society of Cell and Gene Therapy (ISCT), and the Foundation for the Accreditation of Cellular Therapy (FACT), formed a global CAR-T task force to identify and address key questions pertinent for hematologists and transplant physicians regarding the clinical use of anti CD19 CAR-T therapy in patients with B-ALL. This article presents an initial roadmap for navigating common clinical practice scenarios that will become more prevalent now that the first commercially available CAR-T product for B-ALL has been approved.

AB - On August 30, 2017, the U.S. Food and Drug Administration (US-FDA) approved tisagenlecleucel (KYMRIAH, Novartis, Basel, Switzerland), a synthetic bioimmune product of anti-CD19 chimeric antigen receptor-T cells (CAR-T), for the treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). With this new era of personalized cancer immunotherapy, multiple challenges are present ranging from implementation of a CAR-T program to safe delivery of the drug, long-term toxicity monitoring and disease assessments. To address these issues, experts representing the American Society for Blood and Marrow Transplant (ASBMT), the European Group for Blood and Marrow Transplantation (EBMT), the International Society of Cell and Gene Therapy (ISCT), and the Foundation for the Accreditation of Cellular Therapy (FACT), formed a global CAR-T task force to identify and address key questions pertinent for hematologists and transplant physicians regarding the clinical use of anti CD19 CAR-T therapy in patients with B-ALL. This article presents an initial roadmap for navigating common clinical practice scenarios that will become more prevalent now that the first commercially available CAR-T product for B-ALL has been approved.

UR - http://www.scopus.com/inward/record.url?scp=85065970499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065970499&partnerID=8YFLogxK

U2 - 10.1038/s41409-019-0451-2

DO - 10.1038/s41409-019-0451-2

M3 - Article

C2 - 31092900

AN - SCOPUS:85065970499

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

ER -